Tumor News and Research RSS Feed - Tumor News and Research

Study details a new pathway for tumor formation

Study details a new pathway for tumor formation

Researchers at the University of Wisconsin-Madison School of Veterinary Medicine (SVM) have identified the biological mechanism that may give some cancer cells the ability to form tumors in dogs. [More]
Insurance status linked to patient safety, quality of care for patients with brain tumors

Insurance status linked to patient safety, quality of care for patients with brain tumors

Patients that are on Medicaid or uninsured have higher rates of reportable patient safety and quality of care issues during hospitalization for brain tumors, reports a study in the March issue of Neurosurgery, official journal of the Congress of Neurological Surgeons. [More]
Patients who undergo chemo before breast cancer operation more likely to opt for lumpectomy

Patients who undergo chemo before breast cancer operation more likely to opt for lumpectomy

Patients with larger malignant tumors of the breast who undergo chemotherapy before a breast cancer operation are more likely to opt for a breast-preserving procedure and forgo a mastectomy (surgical removal of the breast), according to a new study published online as an "article in press" in the Journal of the American College of Surgeons. [More]
Researchers outline personalized surgical approach to ovarian cancer

Researchers outline personalized surgical approach to ovarian cancer

A surgical algorithm developed and implemented by ovarian cancer specialists at The University of Texas MD Anderson Cancer Center dramatically increases the frequency of complete removal of all visible tumor - a milestone strongly tied to improved survival. [More]
Chiasma closes $70 million Series E financing round

Chiasma closes $70 million Series E financing round

Chiasma, Inc., a U.S. privately-held biopharma company developing octreotide capsules, its lead product for the orphan condition acromegaly, today announced the closing of a $70 million Series E financing round. [More]
Study focuses on improving therapeutic outcomes in cancer patients through diet-drug combination

Study focuses on improving therapeutic outcomes in cancer patients through diet-drug combination

Boosting anti-cancer immunity through diet and novel drug therapies—that's the idea behind a collaborative project involving researchers from the South Dakota State University College of Pharmacy and Sanford Research in Sioux Falls. [More]
Researchers discover that cell's skeleton can trigger cell multiplication

Researchers discover that cell's skeleton can trigger cell multiplication

A research team from Instituto Gulbenkian de Ciencia (IGC; Portugal), led by Florence Janody, in collaboration with Nicolas Tapon from London Research Institute (LRI; UK), discovered that the cell's skeleton can trigger the multiplication of cells through the action of proteins that control cellular rigidity. [More]
EORTC researchers review potential treatment options for patients with locally advanced breast cancer

EORTC researchers review potential treatment options for patients with locally advanced breast cancer

Treating patients with locally advanced inoperable breast cancer is an extremely difficult task. The overwhelming majority of patients treated for this disease suffer relapse and, despite the best multimodal treatment, do not survive. There is a medical need to examine current and potential treatments, and EORTC researchers have recently published an article in Nature Reviews Clinical Oncology concerning this topic. [More]
Targeting stroma could potentially extend survival of pancreatic cancer patients

Targeting stroma could potentially extend survival of pancreatic cancer patients

Like a stealth jet cloaks itself from radar, cancer cells cloak themselves within tumors by hiding behind a dense layer of cellular material known as stroma. [More]
Researchers report that 15% of pancreatic cancer patients may benefit from personalized therapies

Researchers report that 15% of pancreatic cancer patients may benefit from personalized therapies

Cancer researchers at Indiana University report that about 15 percent of people with pancreatic cancer may benefit from therapy targeting a newly identified gene signature. [More]
New online tool helps educate practicing oncologists with therapeutic decision-making for NSCLC

New online tool helps educate practicing oncologists with therapeutic decision-making for NSCLC

A new interactive online tool helps educate practicing oncologists worldwide with therapeutic decision-making for advanced non-small cell lung cancer (NSCLC) based on a patient's molecular and clinical characteristics by providing feedback from an expert panel. [More]
Researchers one step closer to understanding development of glioblastoma

Researchers one step closer to understanding development of glioblastoma

Glioblastomas are a highly aggressive type of brain tumor, with few effective treatment options. Moffitt Cancer Center researchers are one step closer to understanding glioblastoma development following the identification of a key protein signaling pathway involved in brain tumor stem cell growth and survival. [More]
Noble Hospital surgeon to present work on new breast cancer device at Miami Breast Cancer Conference

Noble Hospital surgeon to present work on new breast cancer device at Miami Breast Cancer Conference

A Noble Hospital breast surgeon's work with a new device that improves treatment of breast cancers will be featured later this month at a prestigious international medical conference. [More]
New four-way collaboration aims to improve clinical decision-making in the treatment of colon cancer

New four-way collaboration aims to improve clinical decision-making in the treatment of colon cancer

EKF Diagnostics subsidiary, Selah Genomics, has announced a major, four-way collaboration with Greenville Health System (GHS, South Carolina), DecisionQ Corporation (Virginia), and BD (Becton Dickinson and Company, New Jersey). [More]
Scientists discover DNA vaccine that alleviates chronic inflammation in the body

Scientists discover DNA vaccine that alleviates chronic inflammation in the body

An international team of scientists including CureLab Oncology, Inc. (Boston), University of Camerino (Italy), and Boston University have serendipitously discovered a DNA vaccine, which systemically alleviates chronic inflammation in the body. Since osteoporosis is an inflammatory disease, preventive and therapeutic effects of the new vaccine were demonstrated on mouse models with osteoporosis. [More]
Remsima (infliximab) now available in Europe for treatment of autoimmune diseases

Remsima (infliximab) now available in Europe for treatment of autoimmune diseases

Celltrion Healthcare has today announced the launch of Remsima (infliximab) in 12 European markets: Austria, Belgium, Denmark, France, Germany, Greece, Italy, Luxembourg, the Netherlands, Spain, Sweden and the UK. [More]
AR-V7 status does not affect response to taxane chemotherapy in patients with mCRPC

AR-V7 status does not affect response to taxane chemotherapy in patients with mCRPC

Findings from a small prospective study suggest that androgen receptor V7 (or AR-V7) status does not significantly affect response to taxane chemotherapy in men with metastatic castration-resistant prostate cancer (mCRPC). Treatment outcomes were largely similar for the 17 patients with AR-V7-positive prostate cancer and the 20 patients with AR-V7-negative disease included in this analysis. [More]
Sorafenib, sunitinib provide no benefit to patients with locally advanced kidney cancer

Sorafenib, sunitinib provide no benefit to patients with locally advanced kidney cancer

Findings from a federally funded study suggest that patients with locally advanced kidney cancer should not be treated with either adjuvant (post-surgery) sorafenib or sunitinib. The average period to disease recurrence was similar between those who received sorafenib or sunitinib after surgery (5.6 years) and those treated with placebo (5.7 years). [More]
New TAU study may offer hope to people diagnosed with Glioblastoma multiforme

New TAU study may offer hope to people diagnosed with Glioblastoma multiforme

There are no effective available treatments for sufferers of Glioblastoma multiforme (GBM), the most aggressive and devastating form of brain tumor. The disease, always fatal, has a survival rate of only 6-18 months. [More]
Study shows that even breast cancers with few androgen receptors benefit from anti-androgen therapy

Study shows that even breast cancers with few androgen receptors benefit from anti-androgen therapy

A University of Colorado Cancer Center study published today in the journal Molecular Cancer Therapeutics shows that only about 1 percent of triple-negative breast cancer cells in a tumor must be "androgen-receptor-positive" to show benefit from anti-androgen therapies. [More]